Search Results 991-1000 of 18935 for Neutrophil

1. A Study Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma - Mayo Clinic

   Absolute Neutrophil Count ≥ 1,500/mm^3;; Platelet Count ≥ 100,000/mm3;; Hemoglobin ≥ 10 mg/dL* ;; Total Bilirubin ≤ 1.5 x upper limit of normal (ULN)** ...

2. Low-Dose or High-Dose Lenalidomide in Treating Children with Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma - Mayo Clinic

   Peripheral absolute neutrophil count (ANC) ≥ 1,000/uL; Platelet count ≥ 100,000/uL (transfusion independent); Hemoglobin ≥ 8.0 g/dL (may receive red blood ...

3. LS1681: A Study of AR160 in Treating Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1500/mm^3. Platelet count ≥ 75,000/mm^3. Hemoglobin ≥ 8.0g/dL. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or ...

4. Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1500/mm^3; Platelet count ≥ 75,000/mm^3; Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or if total bilirubin is ...

5. Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer - Mayo Clinic

   Bone marrow reserve consistent with absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L; platelet count ≥ 100 x 10^9/L; hemoglobin ≥ 9 g/dL; Total bilirubin ...

6. A Study to Evaluate Non-Operative Management and Early Response Assessment in Rectal Cancer - Mayo Clinic

   - Absolute neutrophil count (ANC) > 1,500 cells/mm3 - Hemoglobin> 8 g/dl - Platelets >100,000 cells/mm3 - Women of childbearing potential and men must agree ...

7. Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1500 cells/L; Platelets ≥ 100,000 u/L; Creatinine ≤ 1.5 x upper limit of normal (ULN); Serum glutamic oxaloacetic ...

8. A Study of the Safety and Drug/Body Interactions of BGB-3111 for Patients with B-Cell Lymphoid Malignancies - Mayo Clinic

   ... neutrophils < 1.0 x 10^9/L due to marrow infiltration are allowed to receive growth factors to bring pre-treatment neutrophils to ≥ 1.0 x 10^9/L. Adequate ...

9. A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433 - Mayo Clinic

   Absolute neutrophil count (ANC) < 1,000/µL;; Platelet count < 50,000/µL;; Absolute lymphocyte count < 500/µL;; Hemoglobin < 8 g/dL. Enrollment in another ...

10. A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment - Mayo Clinic

    Absolute neutrophil count (ANC) ≥ 1500/mm^3 without the use of hemopoietic growth factors within the last 7 days prior to randomisation;; Platelet count ...